Compare DLPN & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLPN | NCEL |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 20.7M |
| IPO Year | N/A | N/A |
| Metric | DLPN | NCEL |
|---|---|---|
| Price | $1.52 | $2.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 37.7K | ★ 91.3K |
| Earning Date | 11-12-2025 | 12-01-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $53,371,115.00 | N/A |
| Revenue This Year | $10.62 | N/A |
| Revenue Next Year | $13.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.86 | N/A |
| 52 Week Low | $0.75 | $2.48 |
| 52 Week High | $1.88 | $7.64 |
| Indicator | DLPN | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 37.11 | N/A |
| Support Level | $1.41 | N/A |
| Resistance Level | $1.65 | N/A |
| Average True Range (ATR) | 0.09 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 17.27 | 0.00 |
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.